Summit Therapeutics (SMMT) – Research Analysts’ Recent Ratings Updates
by Jessica Moore · The Cerbat GemSeveral brokerages have updated their recommendations and price targets on shares of Summit Therapeutics (NASDAQ: SMMT) in the last few weeks:
- 5/21/2026 – Summit Therapeutics is now covered by Sanford C. Bernstein. They set an “underperform” rating on the stock.
- 5/18/2026 – Summit Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
- 5/10/2026 – Summit Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
- 5/4/2026 – Summit Therapeutics had its price target lowered by HC Wainwright from $30.00 to $23.00. They now have a “buy” rating on the stock.
- 5/2/2026 – Summit Therapeutics was upgraded by Wall Street Zen from “strong sell” to “sell”.
- 5/1/2026 – Summit Therapeutics had its price target lowered by Piper Sandler from $17.00 to $16.00. They now have a “neutral” rating on the stock.
- 4/21/2026 – Summit Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 4/8/2026 – Summit Therapeutics is now covered by Citigroup Inc.. They set a “buy” rating on the stock.
- 4/8/2026 – Summit Therapeutics is now covered by Stifel Nicolaus. They set a “buy” rating and a $45.00 price target on the stock.
- 3/25/2026 – Summit Therapeutics was upgraded by Truist Financial Corporation to “strong-buy”.
Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.
Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.